Make earlier prevention against the diseases that shorten healthspan accessible to everyone.
We envision a future where people can recognize meaningful biological change before symptoms appear and act earlier to protect more healthy years.
About miRoncol Health
Built for the years before symptoms.
miRoncol is building a microRNA intelligence company around an ambitious preventive-health idea: recognize meaningful biological change earlier, understand it in personal context and help protect more years of healthy life.
CompanyCanadian preventive-health biotechnology
Core layermicroRNA intelligence
CapabilitiesNGS, AI analytics and targeted PCR
First applicationmiCheckup Early Cancer Detection Test
Why we exist
Earlier knowledge can create more possibility.
The company is organized around prevention—not waiting for disease to become obvious, but building the science, data and applications that can help make biological change visible sooner.
Build microRNA intelligence for preventive health.
Use convenient biological samples, AI-assisted pattern recognition and longitudinal data to recognize meaningful change earlier—and translate validated signals into focused tests.
“A single test captures the moment. Longitudinal intelligence helps us understand the change.”
Victoria Xu · Co-Founder & Chief Executive Officer
Leadership
The team behind the intelligence.
Leadership spanning company building, bioinformatics, oncology, molecular diagnostics and clinical validation.
Victoria Xu
Co-Founder & Chief Executive Officer
BIOINFORMATICS · PUBLIC MANAGEMENT · COMPANY STRATEGY
An entrepreneur and investor with graduate training in bioinformatics and public management. Victoria leads miRoncol’s strategy, operations and path from scientific opportunity to preventive-health applications.
inConnect on LinkedIn
Christopher M. Gallagher, MD
Co-Founder & Chief Medical Officer
20+ YEARS · MEDICAL ONCOLOGY · CLINICAL RESEARCH
A practicing medical oncologist with more than 20 years in cancer care and clinical research. Chris guides miRoncol’s clinical strategy, scientific discipline and patient-centred application.
inConnect on LinkedIn
Gilles Erb, PhD
Medical & Scientific Director
FORMER ROCHE (FMI) SCIENTIFIC DIRECTOR · DIAGNOSTICS
Gilles brings more than 20 years in oncology diagnostics and clinical validation, including experience as Global Scientific Director for Integrated Molecular Medicine at Roche (FMI).
inConnect on LinkedIn
Hai Hu, PhD
Co-Founder & Chief Scientific Officer
BIOINFORMATICS · MICRORNA MODELS · PEER-REVIEWED RESEARCH
An award-winning bioinformatics scientist and the scientific architect behind miRoncol’s peer-reviewed blood-based microRNA models for multi-cancer early detection.
inConnect on LinkedInScientific Advisory Board
External perspective. Scientific accountability.
Physicians, scientists and biotechnology leaders contribute perspective across diagnostics, oncology, neuroscience, commercialization and clinical translation.
Beth Rogozinski
CEO, Oncoustics
Product and commercialization leadership across AI diagnostics, digital health and regulated medical technology.
Jiah Pearson-Leary, PhD
CEO, Spire BioAdvisory
Translational neuroscience and full-cycle biotechnology strategy from scientific insight to viable application.
Vinona Bhatia, MD, MPH
Principal, Atapir
Clinical, regulatory and investment perspective across oncology, AI-enabled monitoring and startup development.
Hallgeir Rui, MD, PhD
Professor, Thomas Jefferson University
Physician-scientist expertise connecting molecular cancer biology with translational oncology and clinical questions.
Jerry Lee, PhD
Professor, University of Southern California
A systems-level view of engineering, physics and oncology applied to collaborative cancer early-detection research.
What guides the work
Ambition with discipline.
The platform vision is broad. Every application still has to earn its place through evidence, validation and responsible use.
Prevention first
Build for the earlier, asymptomatic window when additional information may create more options.
Evidence before assertion
Distinguish clearly between published evidence, active research directions and future possibilities.
Complement clinical care
Develop screening and research information to support—not replace—physician-led diagnosis and treatment.
Design toward accessibility
Use broad discovery and focused assays to pursue applications that can become practical at increasing scale.
Build with us
Earlier insight is a multidisciplinary challenge.
miRoncol welcomes conversations with researchers, clinicians, health organizations and partners who share the commitment to responsible preventive innovation.